Business Context and Reporting Period
This Form 8-K Current Report was filed by Pediatrix Medical Group, Inc. on January 14, 2025, covering events occurring on January 12, 2025. The filing addresses a significant change in executive leadership, specifically the appointment of a new Chief Executive Officer (CEO) and the departure of the former CEO.
Key Financial Metrics and Compensation
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data presented relates exclusively to the compensation package for the newly appointed CEO, Mr. Mark S. Ordan:
- Annual Base Salary: $1,000,000.
- Retention Award: One-time cash payment of $2,000,000, payable within 30 days of the effective date.
- Performance Bonus: Target opportunity of 150% of base salary ($1,500,000).
- Equity Transformation Award: Performance share units for 640,000 shares, vesting based on stock price hurdles (125%, 150%, and 175% of the average closing price preceding the effective date).
- Annual Equity Grants: Target grant date fair value of no less than $5,500,000 per year.
Material Changes Versus Prior Period
The primary material change is the leadership transition effective January 12, 2025:
- Appointment: Mr. Mark S. Ordan was appointed CEO and principal executive officer, succeeding Dr. James D. Swift. Mr. Ordan will continue to serve as a Board member and Chair but will not receive separate compensation for Board service.
- Departure: Dr. James D. Swift's tenure as CEO ended. His departure is classified as a termination without "Cause" under his existing employment agreement, entitling him to benefits upon execution of a general release of claims.
Outlook, Risks, and Contingencies
Employment Terms and Severance: Mr. Ordan's employment agreement has an initial five-year term with automatic annual renewals. The agreement includes significant severance protections:
- Standard Termination: For termination without "Cause" or resignation for "Good Reason," Mr. Ordan is eligible for two times base salary, two times the greater of average or target bonus, a pro rata bonus, and acceleration of outstanding equity awards.
- Change in Control: If termination occurs within six months prior to or twelve months following a Change in Control, severance increases to three times base salary, three times the greater of average or target bonus, a pro rata bonus, and acceleration of equity awards (deemed achieved at the greater of target or actual performance).
- Restrictions: The agreement includes customary non-competition, non-solicitation, non-disparagement, and confidentiality provisions.
Risk Factors: The filing notes that the $2 million retention award is subject to pro-rata repayment if Mr. Ordan voluntarily resigns (other than for "Good Reason") or is terminated for "Cause" within three years of the effective date.
Important Facts for Investor Verification
- Verify the specific stock price hurdles and the average closing price used to calculate the vesting conditions for the 640,000 performance share units.
- Confirm the exact terms of Dr. James D. Swift's severance package as detailed in the referenced Proxy Statement and his employment agreement.
- Review the full Employment Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2025) for detailed definitions of "Cause," "Good Reason," and performance metrics.
- Monitor the company's stock price performance relative to the 125%, 150%, and 175% thresholds required for Mr. Ordan's equity award vesting.